

## Biophytis Appoints of Roger A. Fielding, Ph.D., as a Scientific Consultant for Company's SARCOB Clinical Development Program

Paris (France) & Cambridge (Mass), 11 December 2015 – Biophytis (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced today the appointment of Roger A. Fielding, Ph.D., as a scientific consultant to support the Company's SARCOB clinical development program. Dr. Fielding will contribute to the Company's clinical development and regulatory strategies by creating clinical development plans and protocols for Biophytis' product candidates and clinical trials, as well as drafting regulatory materials. He will also serve as a scientific advisor to Biophytis for meetings with national and international medical and pharmaceutical regulators, agencies, and authorities.

*"We are excited to have Dr. Fielding join our team as we continue to move forward with our SARCOB development program,"* said Stanislas Veillet, Ph.D., CEO of Biophytis. *"His expertise and vast experience in geriatric health will be invaluable to us as we will conduct our first Phase IIb clinical trial in 2016. Dr. Fielding will have an important role in developing Biophytis' clinical and regulatory strategies and we look forward to his contributions."*

Dr. Fielding is currently a Professor at the Friedman School of Nutrition Science and Policy at Tufts University. He is also Senior Scientist and Director of the Nutrition, Exercise Physiology, and Sarcopenia Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging, a Lecturer on Physical Medicine and Rehabilitation at Harvard Medical School's Department of Physical Medicine and Rehabilitation and a Professor of Medicine at Tufts University School of Medicine. Dr. Fielding's primary research focus is on the impact of exercise and physical activity on successful human aging, skeletal muscle alterations with advancing age in disabled and non-disabled populations, and age-related alterations in the control of skeletal muscle protein turnover. He is a Member of the Brookdale Institute on Aging; a Charter Member of Aging Systems and Geriatrics Study Section of the PHS National Institutes of Health; and a Member of the American Federation for Aging Research at the National Scientific Advisory Council. Dr. Fielding received his Doctorate in Nutrition from the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University.

Sarcopenic obesity is a pathology that is increasingly common in an aging population. SARCOB drug candidates are orally available selective MAS receptor agonists, which have demonstrated preclinical proof of concept – specifically the anabolic growth of muscle (i.e. increased muscle fiber diameter, increased protein density and inhibition of myostatin) – in models of sarcopenic obesity. Preparations for mid-stage (Phase IIb) clinical testing of SARCOB BIO101 are ongoing. To learn more, please visit: <http://www.biophytis.com/en/pipeline/plateforme-sarcob/>

**Biophytis SA** ([www.biophytis.com](http://www.biophytis.com)), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry age-related macular degeneration (AMD).

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also

collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime.

**Biophytis**

**Stanislas Veillet**

CEO

contact@biophytis.com

Tel : +33 1 41 83 66 00

**Milestones**

**Bruno Arabian**

barabian@milestones.fr

Tel : +33 1 83 62 34 84

Mob : +33 6 87 88 47 26

**LifeSci Advisors**

**Chris Maggos**

Managing Director, Europe

chris@lifesciadvisors.com

Mob : +41 79 367 6254